Mirum Pharmaceuticals, Inc. (FRA:08D)
Germany · Delayed Price · Currency is EUR 60.00
0.00 (0.00%)
Last updated: Nov 26, 2025, 3:29 PM CET
Mirum Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
| 471.79 | 336.89 | 186.37 | 77.06 | 19.14 | - | Upgrade | |
Revenue Growth (YoY) | 53.66% | 80.76% | 141.85% | 302.67% | - | - | Upgrade |
Cost of Revenue | 94.76 | 81.64 | 47.04 | 12.37 | 1.9 | - | Upgrade |
Gross Profit | 377.04 | 255.25 | 139.34 | 64.69 | 17.24 | - | Upgrade |
Selling, General & Admin | 239.73 | 202.22 | 145.88 | 89.07 | 59.22 | 22.69 | Upgrade |
Research & Development | 179.1 | 140.63 | 102.61 | 106.84 | 131.43 | 81.61 | Upgrade |
Operating Expenses | 418.83 | 342.85 | 248.49 | 195.91 | 190.65 | 104.3 | Upgrade |
Operating Income | -41.79 | -87.61 | -109.15 | -131.22 | -173.41 | -104.3 | Upgrade |
Interest Expense | -14.37 | -14.31 | -15.11 | -15.98 | -17.59 | -0.34 | Upgrade |
Interest & Investment Income | 12.51 | 13.79 | 13.74 | 3.86 | 0.37 | 1.56 | Upgrade |
Currency Exchange Gain (Loss) | 1 | 1.2 | 1.8 | - | - | - | Upgrade |
Other Non Operating Income (Expenses) | 1.82 | 0.01 | -4.62 | 1.27 | 106.69 | -0.19 | Upgrade |
EBT Excluding Unusual Items | -40.83 | -86.91 | -113.35 | -142.07 | -83.95 | -103.26 | Upgrade |
Other Unusual Items | - | - | -49.08 | - | - | - | Upgrade |
Pretax Income | -40.83 | -86.91 | -162.42 | -142.07 | -83.95 | -103.26 | Upgrade |
Income Tax Expense | 0.59 | 1.03 | 0.99 | -6.41 | 0.04 | 0.01 | Upgrade |
Net Income | -41.42 | -87.94 | -163.42 | -135.67 | -83.99 | -103.27 | Upgrade |
Net Income to Common | -41.42 | -87.94 | -163.42 | -135.67 | -83.99 | -103.27 | Upgrade |
Shares Outstanding (Basic) | 49 | 48 | 41 | 34 | 30 | 25 | Upgrade |
Shares Outstanding (Diluted) | 49 | 48 | 41 | 34 | 30 | 25 | Upgrade |
Shares Change (YoY) | 4.69% | 16.23% | 20.31% | 12.07% | 20.08% | 119.84% | Upgrade |
EPS (Basic) | -0.84 | -1.85 | -4.00 | -4.01 | -2.77 | -4.09 | Upgrade |
EPS (Diluted) | -0.84 | -1.85 | -4.00 | -4.02 | -2.77 | -4.09 | Upgrade |
Free Cash Flow | 44.32 | 9.33 | -71.05 | -120.41 | -132.78 | -89.3 | Upgrade |
Free Cash Flow Per Share | 0.90 | 0.20 | -1.74 | -3.54 | -4.38 | -3.54 | Upgrade |
Gross Margin | 79.92% | 75.77% | 74.76% | 83.94% | 90.06% | - | Upgrade |
Operating Margin | -8.86% | -26.00% | -58.57% | -170.28% | -906.12% | - | Upgrade |
Profit Margin | -8.78% | -26.10% | -87.68% | -176.05% | -438.86% | - | Upgrade |
Free Cash Flow Margin | 9.39% | 2.77% | -38.12% | -156.26% | -693.81% | - | Upgrade |
EBITDA | -17.57 | -63.98 | -98.33 | -127.98 | -172.82 | -103.99 | Upgrade |
EBITDA Margin | -3.72% | -18.99% | -52.76% | -166.08% | - | - | Upgrade |
D&A For EBITDA | 24.23 | 23.63 | 10.83 | 3.24 | 0.6 | 0.31 | Upgrade |
EBIT | -41.79 | -87.61 | -109.15 | -131.22 | -173.41 | -104.3 | Upgrade |
EBIT Margin | -8.86% | -26.00% | -58.57% | -170.28% | - | - | Upgrade |
Revenue as Reported | 471.79 | 336.89 | 186.37 | 77.06 | 19.14 | - | Upgrade |
Advertising Expenses | - | 11.5 | 6.3 | 4 | 9.2 | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.